Subject(s)
Deferasirox/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Primary Myelofibrosis/drug therapy , Aged , Deferasirox/pharmacology , Female , Humans , Iron Chelating Agents/pharmacology , Male , Primary Myelofibrosis/complications , Retrospective StudiesABSTRACT
Ruxolitinib is a highly potent JAK2 inhibitor approved for the treatment of myelofibrosis (idiopathic or post-polycythemia vera or post-essential thrombocythemia) and, more recently, for polycythemia vera with an inadequate response to or intolerant of hydroxyurea. The most common adverse events of ruxolitinib include immunosuppression with an increased risk of reactivation of silent infections and increased non-melanoma skin cancer. The known neurological side effects of ruxolitinib are dizziness and headache, but no neurological paroxysmal episodes have been recorded. This report deals with an 80-year-old outpatient woman with polycythemia vera turned into myelofibrosis who experienced neurological episodes of hypoesthesia and weakness of right arm and leg during ruxolitinib treatment.